Meeting
2022 ASCO Annual Meeting
Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma.
Authors
Hua-Jay Jeffery Cherng
MD Anderson Hematology/Oncology Fellowship, Houston, TX
Hua-Jay Jeffery Cherng , Stefan Alig , Yasuhiro Oki , Loretta J. Nastoupil , Luis Fayad , Sattva Swarup Neelapu , Francesco Turturro , Frederick B. Hagemeister , Maria Alma Rodriguez , Hun Ju Lee , Timothy McDonnell , Christopher Flowers , Francisco Vega , Michael Richard Green , Ash A. Alizadeh , Richard Eric Davis , Jason Westin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02529852
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7553)
DOI
10.1200/JCO.2022.40.16_suppl.7553
Abstract #
7553
Poster Bd #
206
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
First Author: Laurie Helen Sehn
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho
Poster
2023 ASCO Annual Meeting
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.
First Author: Lorenzo Falchi
Poster
2020 ASCO Virtual Scientific Program
REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL).
First Author: Manfred Welslau